FDA Cracks Down on Telehealth Weight Loss Drug Marketing & Affiliations

The Food and Drug Administration is increasing scrutiny of telehealth companies marketing compounded versions of weight loss drugs, particularly semaglutide and tirzepatide. Recent FDA warnings highlight concerns that these companies are misleading consumers by implying their products are equivalent to FDA-approved medications like Wegovy, Ozempic, Zepbound, and Mounjaro. This crackdown extends beyond the telehealth platforms themselves, focusing on the network of national medical groups providing the prescriptions.

The core issue centers on compounded drugs. These are created by pharmacies mixing ingredients to create a customized medication, often in response to a prescription for a specific patient demand. While compounding can be legitimate, the FDA does not evaluate these drugs for safety or effectiveness in the same way it does approved medications. The agency’s concern is that telehealth companies are capitalizing on the demand for popular weight loss drugs by offering compounded alternatives, while downplaying the lack of FDA oversight. Lovely Meds, Hello Cake, and MEDVi are among the companies that have received warning letters.

The Role of National Medical Groups

A STAT analysis reveals a significant pattern: many of these telehealth companies don’t directly employ the clinicians who prescribe the medications. Instead, they rely on affiliations with a small number of nationwide medical groups. At least 30% of the companies warned by the FDA in the last six months publicly state affiliations with just four groups: Beluga Health, OpenLoop, MD Integrations, and Telegra. This suggests a shared clinical infrastructure underpinning a large segment of the telehealth weight loss market.

This structure raises questions about the level of medical oversight and the potential for conflicts of interest. While the FDA’s warning letters target the marketing practices of the telehealth companies, the ultimate responsibility for prescribing these medications lies with the clinicians within these affiliated medical groups. The FDA is now examining whether these groups are adequately vetting prescriptions and ensuring patient safety.

Understanding GLP-1 Medications and Compounding

The drugs at the center of this controversy are glucagon-like peptide-1 (GLP-1) receptor agonists. These medications, like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), were originally developed to treat type 2 diabetes. However, they have gained widespread attention for their effectiveness in promoting weight loss. They work by mimicking a natural hormone that regulates appetite and blood sugar levels.

MEDVi, for example, offers compounded versions of these medications, as well as branded Ozempic®, positioning itself as a more affordable alternative to traditional pharmacies where these drugs can cost over $1,000 per month. MEDVi’s website advertises compounded medications starting at $179 for the first month. However, the FDA warns that compounded drugs are not FDA-approved and should not be presented as equivalent to their branded counterparts.

What the FDA Warning Letters State

The FDA’s warning letter to Lovely Meds, Inc. Dba Lovely Meds, issued September 9, 2025, specifically cites false or misleading claims on the company’s website. These include statements like “Same active ingredient as Wegovy and Ozempic” and “Same active ingredient as Zepbound & Mounjaro.” The FDA emphasizes that these claims imply equivalence to FDA-approved products, which is not the case for compounded drugs.

The FDA’s concerns are rooted in sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA). These sections prohibit the misbranding of drugs through false or misleading labeling and advertising. The agency asserts that Lovely Meds’ claims violate these provisions, resulting in products being illegally introduced into interstate commerce.

Consumer Risks and Considerations

The rise of telehealth and compounded medications offers potential benefits in terms of accessibility and affordability. However, it also introduces risks. Compounded drugs lack the rigorous quality control and safety testing of FDA-approved medications. There is no guarantee that the ingredients are of the correct purity or dosage, or that the drug is manufactured under sterile conditions.

the long-term effects of compounded GLP-1 medications are unknown. The FDA-approved versions have undergone extensive clinical trials to assess their safety and efficacy, but the same cannot be said for compounded alternatives. Consumers considering these options should be aware of these risks and discuss them with a qualified healthcare professional.

What Comes Next: Increased Scrutiny and Potential Enforcement

The FDA’s recent actions signal a heightened focus on the telehealth industry and the marketing of compounded drugs. The agency is likely to continue issuing warning letters and conducting inspections of telehealth companies and affiliated medical groups. It is also possible that the FDA will pursue more aggressive enforcement actions, such as seeking injunctions to stop the sale of illegally marketed products or bringing criminal charges against companies that violate the FDCA.

Beyond the FDA’s enforcement efforts, it is likely that state medical boards will also increase their scrutiny of clinicians prescribing compounded medications through telehealth platforms. This could lead to disciplinary actions against doctors who are found to be engaging in inappropriate prescribing practices. Consumers should verify the credentials and licensing of any healthcare provider they consult with online, and report any concerns to their state medical board.

The FDA’s actions also underscore the need for clearer regulations governing the compounding of drugs and the practice of telehealth. As the telehealth market continues to grow, it is essential to strike a balance between promoting innovation and protecting patient safety. Ongoing monitoring of adverse events and continued research into the safety and efficacy of compounded medications will be crucial in informing future policy decisions.

For more information on FDA regulations and warnings, visit the FDA website. Individuals considering GLP-1 medications for weight loss should consult with a qualified healthcare provider to discuss the risks and benefits of all available options.